About
Sandra Glucksmann joined Adjuvant Capital as an Advisory Partner and Investment Committee member in 2023, and is CEO of Sensorium Therapeutics. She has over 30 years in biotech, serving as founding CEO and President of Cedilla Therapeutics and founding COO of Editas Medicine. She holds a Ph.D. in molecular genetics and cell biology from the University of Chicago.
Invests in
Biotech
Experience
- Rouge TherapeuticsBoard Executive Chaircurrent2025 — presentNetherlands
- Tufts University School of MedicineTUSM Board of Advisorscurrent2024 — presentBoston, Massachusetts, United States
- REGENXBIO Inc.Independent Board Membercurrent2018 — presentRockville, MD
- Adjuvant CapitalAdvisory Partnercurrent2023 — presentUnited States
- Edity TherapeuticsBoard Membercurrent2022 — presentRehovot, Israel
- Scenic BiotechSenior Advisorcurrent2024 — presentAmsterdam, North Holland, Netherlands
- Scenic BiotechIndependent Board Member2017 — 2024The Randstad, Netherlands
- Sensorium TherapeuticsBoard Member and Senior Advisor2025
- Sensorium TherapeuticsPresident & CEO2023 — 2025Boston, Massachusetts, United States
- Cedilla TherapeuticsPresident and CEO2018 — 2022Cambrdige, MA
- WEST - Women in the Enterprise of Science and TechnologyMember Board of Directors2017 — 2020Cambridge, MA
- WEST - Women in the Enterprise of Science and TechnologyChair Board of Directors2006 — 2017Cambridge, MA
- Third Rock VenturesEntrepreneur In Residence2017 — 2018
- Editas MedicineChief Operating Officer2013 — 2017
- TaconicIndependent Board Member2006 — 2015
- Cerulean PharmaSenior VP Research and Development2006 — 2013Cambridge, MA
- Cerulean PharmaSenior VP Research & Business Operations2006 — 2011
- Millennium PharmaceuticalsFrom Scientist to VP1993 — 2006
Skills & more
Research1Biotechnology32Lifesciences8Commercialization5Technology Transfer5Medical Devices3Molecular Biology7Biochemistry5Start-ups5Cross-functional Team Leadership4Oncology7Biopharmaceuticals16
+3 more
Drug DiscoveryProduct DevelopmentPharmaceutical IndustryLanguages Spanish
From Alexandra's professional profile.
Investments
Board seats
REGENXBIOScenic Biotech
Per the firm's website.
Colleagues at Adjuvant Capital
Abrar Haque
Associate at Adjuvant Capital
Christian Mandl
Senior Advisor at Adjuvant Capital
Curt LaBelle
Venture Partner at Adjuvant Capital
Evelyn Yanatos
Director of Finance and Compliance at Adjuvant Capital
Gerard Cunningham
Operating Partner at Adjuvant Capital
Giulia Balconi
Associate at Adjuvant Capital
Glenn Rockman
Co-Founder and Partner at Adjuvant Capital
Jim Robinson
Senior Advisor at Adjuvant Capital
Frequently asked questions
- Who is Alexandra (Sandra) Glucksmann?
- Sandra Glucksmann joined Adjuvant Capital as an Advisory Partner and Investment Committee member in 2023, and is CEO of Sensorium Therapeutics. She has over 30 years in biotech, serving as founding CEO and President of Cedilla Therapeutics and founding COO of Editas Medicine. She holds a Ph.D. in molecular genetics and cell biology from the University of Chicago.
- Where does Alexandra (Sandra) Glucksmann work?
- Alexandra (Sandra) Glucksmann is Advisory Partner at Adjuvant Capital.
- What does Alexandra (Sandra) Glucksmann invest in?
- Alexandra (Sandra) Glucksmann invests in Biotech.
- What boards does Alexandra (Sandra) Glucksmann sit on?
- Alexandra (Sandra) Glucksmann holds tracked board seats at REGENXBIO, Scenic Biotech.
- Where did Alexandra (Sandra) Glucksmann go to school?
- Alexandra (Sandra) Glucksmann studied at Massachusetts Institute of Technology (Post-doctoral fellow, Molecular Biology); University of Chicago (PhD Molecular Genetics and Cell Biology); University of Wisconsin-Madison (Bachelor of Science - BS).
Founder mafias
Massachusetts Institute of Technology mafia546
Also came through, then founded or led a company.
Elad GilPhDFounded Brain Co.Nat FriedmanBachelor of ScienceFounded XamarinMatt HuangB.S.Founded HotspotsDelian AsparouhovDropoutFounded Nightingale +1Drew HoustonBSFounded Dropbox +1Arash FerdowsiComputer ScienceFounded Dropbox
+ 539 more
University of Chicago mafia102
Also came through, then founded or led a company.
Bobby PittmanMaster's degreeFounded Oathafrica +2Sean HarperABFounded TransFS +2Bharat KilaruBachelor of Arts (BA)Founded Verano Health +2Matt KrisiloffFounded Preventive +1Robby YungB.A. cum laudeFounded The Sandbox +1Alexis BorisyBachelor's degreeFounded Foundation Medicine +1
+ 95 more
University of Wisconsin-Madison mafia59
Also came through, then founded or led a company.
Chris FernandezBachelor of Science (BS)Founded Mindful Health +1Andy KonwinskiBachelor of Science (B.S.)Founded Perplexity +1Thorbjørn RønjeB.ScFounded Risika +1Gabe KrambsMathematics and Computer ScienceFounded Compound +1Jack PawlikBachelor of Business Administration - BBAFounded Dripos +1Ray LiaoVisiting studentFounded Empallo +1
+ 52 more
Third Rock Ventures mafia16
Also came through, then founded or led a company.
Reid HuberPartnerFounded MOMA Therapeutics +2Christoph LengauerPartnerFounded Celsius Therapeutics +2Steve PaulVenture PartnerFounded Voyager Therapeutics, Inc. +1Alexis BorisyPartnerFounded Foundation Medicine +1Philip ReillyVenture PartnerFounded Luna Genetics +1Abbie CelnikerPartnerFounded Eleven Biotherapeutics
+ 9 more
EdiTy Therapeutics mafia2
Also came through, then founded or led a company.
Same school
Also attended Massachusetts Institute of Technology1,521
Fred WilsonCo-founder & Partner at Union Square VenturesElad GilSolo general partner investing through Gil CapitalAileen LeeFounder & Managing Partner of Cowboy VenturesHemant TanejaCEO & Managing Director of General CatalystNat FriedmanCo-lead of Meta Superintelligence Labs; co-founder of NFDGBrad FeldCo-founder of Foundry and Techstars
+ 1,515 more
Also attended University of Chicago446
Mark SusterManaging Partner at Upfront VenturesShardul ShahInvestor at Index VenturesSam BlackmanEntrepreneur in Residence at GV (Google Ventures)Clay FisherInvestor at Spark CapitalMaria HeyenInvestor at LightbankJonas CiplickasPrincipal at Scale Venture Partners
+ 440 more
Also attended University of Wisconsin-Madison344
Zhenyu TangInvestment Director at Intel CapitalDougAdvisor at Clear VenturesDan RuchPartner at Rho VenturesGeorge RobertsInvestor at OpenView Venture PartnersBret L. BostwickMD, FAAP, FACMG, Venture Advisor at Breyer CapitalKevin WenzelAssociate at Marlin Equity Partners
+ 338 more
Shared employers
Also worked at Tufts University School of Medicine2
Also worked at Scenic Biotech10
Stephan ChristgauFounding Partner at EIR VenturesHaitao HuData Analyst at Linear CapitalMichael WackerManaging Partner at BioMedPartnersEdward van WezelManaging Partner at BioGeneration VenturesThijs Cohen TervaertPartner at InkefAndrew McLeanManaging Partner at Tin Alley Ventures
+ 4 more
Also worked at Third Rock Ventures79
Lisa PurcellInvestor at Third Rock VenturesPaul MeloneInvestor at Third Rock VenturesKevin MunnellyInvestor at Third Rock VenturesAmanda ChanInvestor at Third Rock VenturesJigar RaythathaInvestor at Third Rock VenturesOlie LuchitskyInvestor at Third Rock Ventures
+ 73 more
